Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase Ia/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Patients With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

The purpose of this phase Ia/b study is to evaluate the safety of NGM120 in patients with advanced solid tumors, including pancreatic cancer.

NCT#: NCT04068896
Study ID: 18-0402
Trial Phase: Phase I

Trial Sponsor: NGM Biopharmaceuticals, Inc
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, NGM120

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Back to Trial Search